Table 1.

Baseline Characteristics: Comparison of NEST-1 to NEST-2

Baseline Characteristics		TLT Therapy*			SHAM Therapy*			All†
		NEST-1 (n=79)	NEST-2 (n=331)	P value	NEST-1 (n=41)	NEST-2 (n=327)	P value	NEST-1 (N=120)	NEST-2 (N=658)	P value
Age(y)		70.2	70.4	0.92	68.5	70	0.48	69.63	70.13	0.6800
Female		45.60%	44.70%	0.90	36.60%	41.90%	0.61	42.5%	43.3%	0.92
Ethnicity				<0.001			<0.001			<0.001
White		36.7%	77.3%		41.5%	77.2%		38.3%	77.3%
Black		2.5%	11.2%		0.0%	11.6%		2.0%	11.4%
Hispanic		5.1%	2.1%		4.9%	2.4%		5.0%	2.3%
Other		55.7%	9.4%		53.7%	8.8%		55.0%	9.1%
Mean Time to Rx (Hours)		16.93	14.62	0.001	16.34	14.69	0.11	16.73	14.66	0.0004
Time to Rx strata < 12hr		12.66%	35.65%	<0.001	29.27%	35.78%	0.49	18.3%	35.7%	0.0001
Prior CVA		21.52%	30.51%	0.13	29.27%	33.33%	0.72	24.2%	31.9%	0.106
Diabetes		25.32%	31.42%	0.34	21.95%	33.30%	0.16	24.1%	32.4%	0.086
HTN		55.70%	82.2%	<0.0001	48.80%	83.80%	<0.0001	53.3%	82.9%	<0.0001
Baseline NIHSS (mean)		12.25	13.13	0.13	12.02	13.17	0.12	12.18	13.15	0.03

^*p-values refer to comparison of NEST-1 patients to NEST-2 patients (within a single treatment modality).

^†p-values refer to comparison of NEST-1 patients to NEST-2 patients overall (combining treatment modalities)